Cervical Cancer Treatment Market Trends, Size, Share by 2030
[Research Report] The cervical cancer treatment market is projected to grow from US$ 9,433.94 million in 2022 to US$ 14,074.08 million by 2030; the market is anticipated to record a CAGR of 5.13% from 2022 to 2030.
Market Insights and Analyst View:
The cervical cancer treatment market forecast can help stakeholders to plan their growth strategies.
Cervical cancer refers to the cancer that occurs in the cells of the cervix, i.e., the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening. The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the growth of the market. Cervical cancer treatment market trends include the increasing R&D for cervical cancer diagnosis and drugs.
Growth Drivers and Challenges:
Increasing Prevalence of Cervical Cancer Fuels Cervical Cancer Treatment Market
Across the globe, cancer is becoming one of the main causes of mortality. According to the World Health Organization (WHO), cancer was the top cause of death for individuals under the age of 70 in 183 nations, while in 123 other countries, it was the fourth most common cause of death globally in 2019. Furthermore, according to the data released by the World Health Organization in March 2021, nearly 10 million fatalities in 2020 were attributed to various forms of cancer. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are high in poorer nations due to the late discovery of the disease.
The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~27.5 million, and the disease is likely to cause ~163 million deaths by 2040. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are expected to increase the burden of cancer in the world in the coming years. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.
The lack of awareness about cervical cancer among populations, healthcare providers, and policymakers; limited access to high-quality healthcare services and cervical screening programs; and a lack of functional referral systems are among the factors leading to the high incidence and mortality from cervical cancer. Cervical cancer incidence and mortality have lowered in industrialized countries owing to improved access to cytological screening and rapid treatment of early cervical lesions. It is critical to implement population-based cervical screening and increase its acceptance in low- and middle-income countries (LMICs) to reduce cervical cancer mortality. Raising awareness about risk factors such as first sexual intercourse at a young age and having multiple male sexual partners; the high risk associated with HPV types 8, 9, and 10; first full-term pregnancy at a young age; prolonged use of oral contraceptives; and HIV infections may help boost participation in screening programs. Better awareness regarding the symptoms of cervical cancer, such as intermenstrual vaginal bleeding, postmenopausal vaginal bleeding, post-coital vaginal bleeding, foul vaginal discharge, and lower abdomen pain, might help women seek early help. Thus, the lack of awareness about cervical cancer among populations hinders the cervical cancer treatment market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cervical Cancer Treatment Market: Strategic Insights
Cervical Cancer Treatment Market
-
CAGR (2022 - 2030)
5.13%
-
Market Size 2022
US$ 9,433.94 Million
-
Market Size 2030
US$ 14,074.08 Million
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- F Hoffmann La Roche Ltd
- Merck Sharp
- Dohme Corp
- GlaxoSmithKline plc
- Genentech Inc
- Amgen Inc
- Advaxis Inc
- Biocon
- Allergan Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Type
- Squamous Cell Carcinoma
- Adenosquamous Carcinoma
- Adenocarcinoma
Product
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Therapeutic Vaccines
End User
- Hospital
- Homecare
- Cancer Centers
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cervical Cancer Treatment Market: Strategic Insights
-
CAGR (2022 - 2030)5.13% -
Market Size 2022
US$ 9,433.94 Million -
Market Size 2030
US$ 14,074.08 Million
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- F Hoffmann La Roche Ltd
- Merck Sharp
- Dohme Corp
- GlaxoSmithKline plc
- Genentech Inc
- Amgen Inc
- Advaxis Inc
- Biocon
- Allergan Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Squamous Cell Carcinoma
- Adenosquamous Carcinoma
- Adenocarcinoma
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Therapeutic Vaccines
- Hospital
- Homecare
- Cancer Centers
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Segmentation and Scope:
Segmental Analysis:
Based on type, the market is segmented into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger cervical cancer treatment market share in 2022 and is anticipated to register a higher CAGR during 2022–2030. Based on product, the market is classified as surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. The surgery segment is anticipated to hold a significant share by 2030. In terms of end user, the market is categorized into hospital, homecare, cancer centers, and others. In terms of end user, the hospital segment held the largest cervical cancer treatment market share in 2022.
Regional Analysis:
In terms of geography, the scope of the cervical cancer treatment market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest cervical cancer treatment market share in 2022. In North America, the US holds a significant share. Constantly ongoing R&D activities, financial assistance from governments and other public and private organizations, partnerships between IT and pharmaceutical firms, and the rising incidences of neurological diseases primarily drive market growth in the country. Furthermore, strategic initiatives taken by the government to improve the testing procedures are anticipated to benefit the market during the forecast period. The increasing adoption of regulations pertaining to rare diseases will most likely present an opportunity for market expansion. For example, the American Cancer Society (ACS) revised the cervical cancer screening standards in September 2020.
Cervical Cancer Treatment Market Report Scope
Report Attribute
Details
Market size in 2022
US$ 9,433.94 Million
Market Size by 2030
US$ 14,074.08 Million
Global CAGR (2022 - 2030)
5.13%
Historical Data
2020-2022
Forecast period
2022-2030
Segments Covered
By Type - Squamous Cell Carcinoma
- Adenosquamous Carcinoma
- Adenocarcinoma
By Product - Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Therapeutic Vaccines
By End User - Hospital
- Homecare
- Cancer Centers
Regions and Countries Covered
North America - US
- Canada
- Mexico
Europe - UK
- Germany
- France
- Russia
- Italy
- Rest of Europe
Asia-Pacific - China
- India
- Japan
- Australia
- Rest of Asia-Pacific
South and Central America - Brazil
- Argentina
- Rest of South and Central America
Middle East and Africa - South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
Market leaders and key company profiles
- F Hoffmann La Roche Ltd
- Merck Sharp
- Dohme Corp
- GlaxoSmithKline plc
- Genentech Inc
- Amgen Inc
- Advaxis Inc
- Biocon
- Allergan Inc
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 9,433.94 Million |
Market Size by 2030 | US$ 14,074.08 Million |
Global CAGR (2022 - 2030) | 5.13% |
Historical Data | 2020-2022 |
Forecast period | 2022-2030 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Industry Developments and Future Opportunities:
The cervical cancer treatment market analysis is carried out by identifying and evaluating key players operating in the market. A few initiatives taken by key market players are listed below:
- In January 2024, Pfizer Inc. and Genmab A/S announced that the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) to convert TIVDAK's (tisotumab vedotin-tftv) approval for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses on or after first-line therapy. With a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024, the application has been awarded Priority Review.
- In September 2023, Guangzhou Gloria Biosciences (GloriaBio) announced that Zimberelimab injection (YuTuo, GLS-010), a fully human anti-PD-1 monoclonal antibody, has been approved for marketing by the China National Medical Products Administration (NMPA). The injection can be used as a monotherapy to treat patients with recurrent or metastatic cervical cancer (R/M CC). The third immune checkpoint inhibitor (ICI) antibody approved worldwide for treating cervical cancer is zimberelimab—the first and only one authorized in China.
Competitive Landscape and Key Companies:
F. Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca are a few key companies profiled in the cervical cancer treatment market report. These companies focus on expanding their offerings to meet the growing consumer demand worldwide. Their global presence allows them to serve many customers, subsequently allowing them to expand their market presence.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Product, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The cervical cancer treatment market is expected to be valued at US$ 14,074.08 million in 2030.
Based on type, the cervical cancer treatment market is segmented into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger cervical cancer treatment market share in 2022 and is anticipated to register a higher CAGR during 2022–2030.
The cervical cancer treatment market was valued at US$ 9,433.94 million in 2022.
Based on product, the market is divided into surgery radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines..
Cervical cancer refers to the cancer that occurs in the cells of the cervix, i.e., the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening.
The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the growth of the market. Cervical cancer treatment market trends include the increasing R&D for cervical cancer diagnosis and drugs
The cervical cancer treatment market has major market players, including F. Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca.
The List of Companies - Cervical Cancer Treatment Market
- F. Hoffmann-La Roche Ltd
- Merck Sharp
- Dohme Corp.
- GlaxoSmithKline plc.
- Genentech, Inc.
- Amgen Inc.
- Advaxis, Inc.
- Biocon
- Allergan, Inc
- Pfizer Inc
- AstraZeneca